Although this study presents limited data on efficacy and long-term adverse effects, our group is currently conducting a phase 1 trial of combination Ad-CCL21-DC and checkpoint inhibition in patients with stage IIIB and IV NSCLC.28 This evidence concerns the gene DCX and non-small cell lung carcinoma.